Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.51 |
| ▸ | APLNR | P35414 | 2/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.48 |
| ▸ | NMBR | P28336 | 1/20 | 0.47 |
| ▸ | GRPR | P30550 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30439872 | 0.89 | C5AR1 (0.60) | C5AR1NMBRGRPR | |
| SCHEMBL30439719 | 0.88 | C5AR1 (0.62) | C5AR1NMBRGRPRCTSLCTSS | |
| SCHEMBL30439794 | 0.88 | C5AR1 (0.60) | C5AR1NMBRGRPRCTSLCTSS | |
| SCHEMBL30439962 | 0.88 | C5AR1 (0.61) | PIN1C5AR1NMBRGRPRCTSL | |
| SCHEMBL30439961 | 0.88 | C5AR1 (0.55) | PIN1APLNRC5AR1NMBRGRPR | |
| SCHEMBL30439960 | 0.87 | C5AR1 (0.57) | OPRM1OPRK1C5AR1 | |
| SCHEMBL30439604 | 0.86 | C5AR1 (0.64) | C5AR1NMBRGRPR | |
| SCHEMBL30440054 | 0.86 | C5AR1 (0.64) | C5AR1NMBRGRPRCTSLCTSS | |
| SCHEMBL30439693 | 0.85 | C5AR1 (0.65) | C5AR1NMBRGRPRCTSLCTSS | |
| SCHEMBL30439951 | 0.85 | CTSL (0.64) | C5AR1NMBRGRPRCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | PIN1 1211/4885APLNR 189/4885OPRM1 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.